HOME >> BIOLOGY >> NEWS
Tigecycline - antibiotic evaluated in surveillance trial

International Health Management Associates, Inc. (IHMA) has been commissioned to conduct the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), a global in vitro surveillance study for tigecycline, a broad-spectrum antibiotic currently under investigation. The study will evaluate the activity of tigecycline against a variety of bacteria, including strains resistant to currently approved drugs, at approximately 690 hospitals in approximately 35 countries over the next three years. Tigecycline is an injectable glycylcycline, a new class of antibiotics, being developed by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"T.E.S.T. is likely one of the largest surveillance studies of its kind ever undertaken. The trial will evaluate the activity of tigecycline against a wide range of clinical pathogens collected from diverse patient populations worldwide. Almost all bacterial strains have developed some level of antibiotic resistance, so this study will enable us to document with in vitro laboratory data the activity of this new antibiotic against bacterial pathogens, including those exhibiting multiple antibiotic resistance," said Daryl Hoban, Ph.D., Director of Clinical and Laboratory Services.

About T.E.S.T.
T.E.S.T. investigators will collect and evaluate clinically significant isolates from a variety of infection sites. The isolates will be tested in vitro to evaluate the activity of tigecycline compared with currently available antimicrobial agents.

The T.E.S.T. data will build upon the drug's in vitro data collected in ongoing Phase 2 and Phase 3 clinical trials in patients. Phase 2 clinical trials investigated use of tigecycline to treat complicated skin and skin-structure or complicated intra-abdominal infections. Phase 3 clinical trials are nearing completion. Laboratory tests from clinical trials have examined tigecycline's activity against a broad spectrum of pathogens, including gram-positive, gram
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
19-May-2004


Page: 1 2

Related biology news :

1. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Smart antibiotics may result from UCLA research
4. K-State researcher working to improve alternatives to equine antibiotics
5. Bacterial protein recycling factor possible key to new class of antibiotics
6. Bacteria spill their guts to aid researchers in quest for new antibiotics
7. Molecule that blocks key bacterial enzyme may lead to new antibiotics
8. Does antibiotic use contribute to allergies?
9. Data show investigational antibiotic safe, effective in preventing travelers diarrhea
10. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study
11. New York microbiologists awarded research grants in antibiotic resistance and lyme disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2019)... ... August 29, 2019 , ... Advancements with Ted Danson ... an upcoming episode, which is scheduled to broadcast 1Q/2020. Check local listings for ... cost-effective robotic surgical solutions for the treatment of patients suffering from spinal disorders. ...
(Date:8/27/2019)... ... ... Shoreline Biome , a microbiome research company that develops tools for ... CEO and Karen Woodward as its VP of Business Development. , These two ... and expand the company’s sales worldwide. , Prior to joining Shoreline Biome, Bill McKenzie ...
(Date:8/27/2019)... Fla. (PRWEB) , ... August 27, 2019 , ... ... in life science and drug development. This episode is scheduled to broadcast 4Q/2019. ... explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show will ...
Breaking Biology News(10 mins):
(Date:8/27/2019)... (PRWEB) , ... August 27, 2019 , ... ... engineering firm, is pleased to announce it has promoted Consulting Engineer, Robert Battista, ... Battista has added the responsibility of onboarding and mentoring new engineers as well ...
(Date:8/23/2019)... ... ... The EnozoPro® converts ordinary tap water into a sanitizing spray capable of ... including E. Coli, Salmonella, MRSA, Listeria and Legionella. It works as a cleaner, sanitizer ... page at rovingblue.com , ”At Enozo, our mission is to develop solutions to replace ...
(Date:8/15/2019)... , ... August 15, 2019 , ... ... Advisory Board. Mr. Lawrence is a member of the Institute of Food Technologists ... and Health (IFSH) Advisory Board, Joint Institute for Food Safety and Applied Nutrition ...
(Date:8/14/2019)... ... 13, 2019 , ... Chata was founded in ... laboratories. After gaining a few significant clients, Lifecycle purchased the company with the ... of manufacturing processing solutions, including reagents for tissue processing. Chata quickly outgrew the ...
Breaking Biology Technology:
Cached News: